Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor

Leuk Lymphoma. 2016 Oct;57(10):2452-5. doi: 10.3109/10428194.2016.1142087. Epub 2016 Feb 17.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Child
  • Choice Behavior*
  • Cities
  • Female
  • Health Services Accessibility / statistics & numerical data
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality*
  • Male
  • Medically Underserved Area
  • Middle Aged
  • Protein Kinase Inhibitors / classification
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Survival Analysis
  • Urban Population / statistics & numerical data*
  • Vulnerable Populations / statistics & numerical data*
  • Young Adult

Substances

  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases